SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monoth...
Howard Bernstein Study Safety Committee Exchange Commission Company Quarterly Report On Form Biotechnologies Company Trial Resumed Following
Source: pharmiweb.com